Floatz logo

Alisertib

Adult Nasal Type Extranodal NK/T-Cell Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

53 Active assets in the Adult Nasal Type Extranodal NK/T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
PEGASPARGASE
CStone Pharmaceuticals
Phase 4BBB
DEXAMETHASONE
Mingzhi Zhang
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Centre, Singapore
Phase 4BBB
ETOPOSIDE
Tarapeutics Science Inc.
Phase 4BB
Tucidinostat
Ruijin Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Alisertib is also rated in:

Burkitt lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
mantle cell lymphomaDormant
BB
Indicative ·
69 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →